Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief ...

The phar­ma in­dus­try’s DC-based lob­by­ing group urged the fed­er­al gov­ern­ment on Fri­day to get on board with ...

Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...

The FDA has approved Roche’s inavolisib plus Pfizer's Ibrance and fulvestrant in a subtype of breast cancer over a month ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won ...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup ...

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...

When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in ...

CDMOs are increasingly fielding inquiries from biopharma clients on how reliant they are on China for their raw materials, ...